The Choice of Resin-Bound Ligand Affects the Structure and Immunogenicity of Column-Purified Human Papillomavirus Type 16 Virus-Like Particles

Large-scale production and purification of VLP-based vaccines

(2011) Tiago Vicente et al.   JOURNAL OF INVERTEBRATE PATHOLOGY

Multiplexed Serologic Assay for Nine Anogenital Human Papillomavirus Types

(2010) D. Opalka et al.   Clinical and Vaccine Immunology

Current understanding of the mechanism of HPV infection

(2010) John T. Schiller et al.   GYNECOLOGIC ONCOLOGY

Optimizing the secondary structure of human papillomavirus type 16 L1 mRNA enhances L1 protein expression in Saccharomyces cerevisiae

(2010) Hyoung Jin Kim et al.   JOURNAL OF BIOTECHNOLOGY

Influence of Disulfide-Stabilized Structure on the Specificity of Helper T-Cell and Antibody Responses to HIV Envelope Glycoprotein gp120

(2010) D. Mirano-Bascos et al.   JOURNAL OF VIROLOGY

Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix®

(2009) Tino F. Schwarz   ADVANCES IN THERAPY

Advantages and Disadvantages of Current Prophylactic Vaccines Against HPV

(2009) Vicente Madrid-Marina et al.   ARCHIVES OF MEDICAL RESEARCH

Replication and Assembly of Human Papillomaviruses

(2009) M.J. Conway et al.   JOURNAL OF DENTAL RESEARCH

Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines

(2009) C. Schellenbacher et al.   JOURNAL OF VIROLOGY

Tissue-Spanning Redox Gradient-Dependent Assembly of Native Human Papillomavirus Type 16 Virions

(2009) M. J. Conway et al.   JOURNAL OF VIROLOGY

One-step chromatographic purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae

(2009) Hyoung Jin Kim et al.   PROTEIN EXPRESSION AND PURIFICATION

Refining HPV 16 L1 purification from E. coli: Reducing endotoxin contaminations and their impact on immunogenicity

(2009) Lysann Schädlich et al.   VACCINE

Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?

(2009) David C Montefiori et al.   Current Opinion in HIV and AIDS

A Direct Comparison of Human Papillomavirus Type 16 L1 Particles Reveals a Lower Immunogenicity of Capsomeres than Viruslike Particles with Respect to the Induced Antibody Response

(2008) N. Thones et al.   JOURNAL OF VIROLOGY

Mechanisms of Human Papillomavirus Type 16 Neutralization by L2 Cross-Neutralizing and L1 Type-Specific Antibodies

(2008) P. M. Day et al.   JOURNAL OF VIROLOGY

Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae

(2008) Min-A Park et al.   PROTEIN EXPRESSION AND PURIFICATION

Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation

(2007) Lot de Witte et al.   IMMUNOBIOLOGY

Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types

(2007) R. Z. Rizk et al.   JOURNAL OF GENERAL VIROLOGY